29 terminated. 29 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 29 | Terminated 29 |
| Phase 3 | 4 | Terminated 4 |
| Phase 1 | 1 | Terminated 1 |
Follow Dyssomnias: new trials by email Literature Review of Dyssomnias trials Research Report on Dyssomnias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of Lemborexant on the Ability to Sleep During Daytime Lemborexant 5 MG [Dayvigo], Matching Placebo - Shift-Work Sleep Disorder | Phase 2 | Terminated | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | 5 | 2024-01-11 | 2026-05-28 |
| A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery Danavorexton, Placebo - Sleep Apnea | Phase 2 | Terminated | Takeda | 41 | 2023-05-11 | 2025-09-16 |
| The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder suvorexant (SUVO), Placebo - Methamphetamine Use Disorder | Phase 2 | Terminated | The University of Texas Health Science Center, Houston | 7 | 2023-03-09 | 2025-04-29 |
| Bryophyllum Pinnatum Treatment of Anxiety Related to Signs of Preterm Birth Bryophyllum 50% chewable tablets, Placebo - Preterm Labor, Anxiety | Phase 2 | Terminated | Christian Haslinger | 60 | 2022-07-12 | 2023-12-13 |
| Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD Pramipexole, Placebo - Sleep Disorder, Restless Legs Syndrome | Phase 2 / Phase 3 | Terminated | Massachusetts General Hospital | 75 | 2022-01-24 | 2025-09-22 |
| Metabolic Effects of Metformin Therapy in Obstructive Sleep Apnea Metformin + PAP, Placebo oral capsule + PAP - Sleep Apnea, Obstructive | Phase 1 / Phase 2 | Terminated | Pennington Biomedical Research Center | 16 | 2021-01-28 | 2023-01-19 |
| Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence Suvorexant 20 mg, placebo - Insomnia, Alcohol Use Disorder | Phase 2 | Terminated | The Florey Institute of Neuroscience and Mental Health | 22 | 2019-08-26 | 2023-02-15 |
| Investigation of the Efficacy and Safety of CHI-921 in Insomnia. CHI-921, Placebo - Insomnia | Phase 2 | Terminated | Canopy Growth Corporation | 21 | 2019-03-21 | 2020-10-05 |
| Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD Ropinirole, Gabapentin, Placebos - Restless Legs Syndrome, End Stage Renal Disease | Phase 2 | Terminated | University of Alberta | 3 | 2019-02-19 | 2022-07-12 |
| Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome BP 1.4979, Placebo - Restless Legs Syndrome | Phase 2 | Terminated | Bioprojet | 29 | 2018-02-06 | 2020-07-30 |
| Validation of Sleep Apnea Screening Device Phase II Obstructive Sleep Apnea Screening Device - Obstructive Sleep Apnea | Phase 2 | Terminated | University of Michigan | 30 | 2017-11-14 | 2023-01-27 |
| Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia Injectafer® (Ferric Carboxymaltose - FCM), Placebo (Normal Saline) - Restless Legs Syndrome (RLS) | Phase 2 | Terminated | American Regent, Inc. | 70 | 2017-07-10 | 2025-04-11 |
| Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea Ketamine, Control - Sleep Apnea, Obstructive Sleep Apnea | Phase 2 / Phase 3 | Terminated | University of Alabama at Birmingham | 9 | 2016-06-02 | 2019-12-19 |
| OneShot Renal Denervation Registry OneShot Ablation System - Hypertension, Heart Failure | Phase 2 / Phase 3 | Terminated | Medtronic Endovascular | 51 | 2014-07-01 | 2015-09-02 |
| Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients Cyclobenzaprine - Sleep Initiation and Maintenance Disorders, Pain | Phase 2 | Terminated | Lynn Henry | 2 | 2013-08-01 | 2016-04-20 |
| Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children Gabapentin, placebo - Neurologically Impaired, Irritable Mood | Phase 2 | Terminated | Gillette Children's Specialty Healthcare | 2 | 2012-04-01 | 2019-08-02 |
| Efficacy of Aerosal® in the Treatment of Sub-Obstructive Adenotonsillar Hypertrophy and Related Diseases Halotherapy, Placebo - Sleep Apnea, Obstructive | Phase 2 | Terminated | Tecno Sun SRL | 45 | 2012-02-01 | 2012-11-08 |
| Safety and Efficacy of Rasagiline in Restless Legs Syndrome rasagiline, placebo (sugar pill) - Restless Legs Syndrome | Phase 2 / Phase 3 | Terminated | University of Virginia | 52 | 2010-09-01 | 2013-02-11 |
| Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration) Ropinirole immediate release (IR), Placebo - Restless Legs Syndrome | Phase 2 | Terminated | GlaxoSmithKline | 34 | 2009-11-30 | 2018-08-10 |
| Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome aplindore MR tablets or Placebo - Restless Legs Syndrome | Phase 2 | Terminated | Neurogen Corporation | 230 | 2009-02-01 | 2009-10-14 |
Showing 20 of 29. Sign in to see all of them.
Sleep Apnea, Obstructive (8) · Sleep Initiation and Maintenance Disorders (8) · Restless Legs Syndrome (7) · Sleep Apnea Syndromes (6) · Heart Failure (2) · Obesity (2) · Overweight (2) · Alcoholism (1) · Anxiety Disorders (1) · Breast Neoplasms (1) · Cheyne-Stokes Respiration (1) · Chronic Pain (1) · Diabetes Mellitus (1) · Disorders of Excessive Somnolence (1) · Dyslipidemias (1)
Nervous System Diseases (29) · Sleep Wake Disorders (28) · Sleep Disorders, Intrinsic (27) · Mental Disorders (19) · Apnea (11) · Respiration Disorders (11) · Respiratory Tract Diseases (11) · Pathological Conditions, Signs and Symptoms (8) · Parasomnias (7) · Signs and Symptoms (6) · Sleep Apnea Syndromes (5) · Neurologic Manifestations (4) · Cardiovascular Diseases (3) · Chemically-Induced Disorders (3)
Gabapentin (2) · ropinirole (2) · suvorexant (2) · 6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide (1) · Continuous Positive Airway Pressure (1) · Duration of Therapy (1) · Fenofibrate (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Ketamine (1) · Metformin (1) · Pramipexole (1) · Saline Solution (1) · Sugars (1) · TAK-925 (1) · Zolpidem (1)
GlaxoSmithKline (2) · Neurogen Corporation (2) · University of Michigan (2) · American Regent, Inc. (1) · Bioprojet (1) · Canopy Growth Corporation (1) · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal (1) · Christian Haslinger (1) · Gillette Children's Specialty Healthcare (1) · H. Lundbeck A/S (1) · Lynn Henry (1) · Massachusetts General Hospital (1) · Medtronic Endovascular (1) · Merck Sharp & Dohme LLC (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)
United States (14) · France (4) · Canada (3) · Germany (2) · Italy (2) · Spain (2) · Switzerland (2) · Australia (1) · Austria (1) · Finland (1) · Japan (1) · Netherlands (1) · United Kingdom (1)
Andrew Lawrence (1) · Bernad Ravina, MD. MSCE (1) · Devin Brown, MD, MS (1) · Dr M Ware, MD (1) · Giovanni Cizza, M.D. (1) · Heather Webber, PhD (1) · Imad Ghorayeb, MD (1) · Jack Kalbfleisch, PhD (1) · John W Winkelman, MD/PhD (1) · Khaled Khechen, MD (1) · Lewis Morgenstern, MD (1)
PMID 20297950, PMID 21784661, PMID 21799479, PMID 22689694, PMID 23483886, PMID 23734252, PMID 23920422, PMID 24041858, PMID 24482677, PMID 25221387, PMID 26567858, PMID 38346816, PMID 39731508
2005 (1), P30DK072476 (1), R21DA052861 (1)